Down Syndrome (Trisomy 21)

1. Topic Overview (Clinical Overview)

Summary

Down Syndrome (DS) is the most common autosomal chromosomal abnormality and the leading genetic cause of intellectual disability worldwide. It is caused by the presence of an extra copy of chromosome 21 (Trisomy 21), occurring in approximately 1 in 700-800 live births. [1,2] The condition results from three distinct cytogenetic mechanisms: nondisjunction (95%), Robertsonian translocation (3-4%), and mosaicism (1-2%). [3] The risk of nondisjunction trisomy 21 increases exponentially with advancing maternal age, rising from 1 in 1,500 at age 20 to 1 in 100 at age 40. [4]

The clinical phenotype is characterized by distinctive dysmorphic features (upslanting palpebral fissures, epicanthic folds, flat nasal bridge, single palmar crease, brachydactyly), generalized hypotonia, intellectual disability (mild to moderate range), and multiple system involvement. [5] Life expectancy has dramatically improved from less than 10 years in the 1929 to over 60 years currently, primarily due to advances in cardiac surgery, infection prevention, and multidisciplinary care. [6]

Associated medical conditions significantly impact morbidity and mortality:

• Congenital heart disease (40-50%): Atrioventricular septal defect (AVSD) is pathognomonic, occurring in 40-45% of cardiac cases. [7]
• Gastrointestinal anomalies (12%): Duodenal atresia, Hirschsprung disease, imperforate anus. [8]
• Haematological disorders: Transient abnormal myelopoiesis (TAM) in 10% of neonates; 10-20 fold increased risk of acute lymphoblastic leukaemia (ALL) and 500-fold risk of acute megakaryoblastic leukaemia (AMKL). [9,10]
• Endocrine dysfunction: Congenital hypothyroidism (1%), acquired hypothyroidism (15-20% by adolescence). [11]
• Musculoskeletal: Atlantoaxial instability (10-30%), hip dysplasia, ligamentous laxity. [12]
• Sensory impairment: Hearing loss (50-75%), visual problems (60%). [13]
• Neurological: Early-onset Alzheimer's disease with neuropathological changes present in nearly 100% by age 40. [14]

Management is centered on early detection of associated anomalies, multidisciplinary surveillance, developmental intervention, and anticipatory guidance. Modern prenatal screening combines ultrasound markers (nuchal translucency) with biochemical serum markers achieving 85-95% detection rates, while non-invasive prenatal testing (NIPT) using cell-free fetal DNA achieves > 99% sensitivity. [15,16] Postnatal diagnosis is confirmed by karyotype analysis which also identifies the cytogenetic mechanism and informs genetic counseling regarding recurrence risk.

Key Facts

Genetics & Epidemiology:

• Karyotype: 47,XX,+21 or 47,XY,+21 (Free trisomy 21)
• Incidence: 1 in 700-800 live births globally [1,2]
• Maternal Age Risk:
  • "Age 20: 1 in 1,500"
  • "Age 35: 1 in 350"
  • "Age 40: 1 in 100"
  • "Age 45: 1 in 30 [4]"
• Mechanisms:
  • "Nondisjunction: 95% (90% maternal, 10% paternal) [3]"
  • "Robertsonian translocation: 3-4% (most commonly t(14;21))"
  • "Mosaicism: 1-2% (variable phenotype)"

Cardiovascular (40-50%): [7]

• AVSD (complete or partial): 40-45% of cardiac defects
• Ventricular septal defect (VSD): 35%
• Atrial septal defect (ASD): 8%
• Patent ductus arteriosus (PDA): 7%
• Tetralogy of Fallot: 4%
• Pulmonary hypertension risk

Gastrointestinal (12%): [8]

• Duodenal atresia: 2-5% (30% of all duodenal atresia cases have DS)
• Hirschsprung disease: 1% (DS present in 2-10% of Hirschsprung cases)
• Imperforate anus: 1%
• Tracheoesophageal fistula: 1%

Haematological: [9,10]

• Transient abnormal myelopoiesis (TAM): 10% of neonates
• ALL risk: 10-20 fold increased
• AMKL risk: 500-fold increased (median age 1-3 years)
• Excellent chemotherapy response in AMKL

Screening & Diagnosis:

• Combined first trimester screening (NT + β-hCG + PAPP-A): 85-95% detection rate [15]
• NIPT (cell-free DNA): > 99% sensitivity, > 99% specificity [16]
• Confirmatory testing: Amniocentesis or CVS with karyotype
• Postnatal karyotype: Mandatory to confirm diagnosis and mechanism

Clinical Pearls

"AVSD is the Signature Cardiac Lesion": Complete atrioventricular septal defect is the most characteristic heart defect in Down syndrome, occurring in 40-45% of cases with congenital heart disease. Early echocardiography is mandatory in all neonates.

"Double Bubble Sign = Duodenal Atresia": This classic radiological finding represents gastric and duodenal dilatation with distal bowel gas paucity. Approximately 30% of infants with duodenal atresia have Down syndrome.

"TAM is a Unique Neonatal Disorder": Transient abnormal myelopoiesis (transient myeloproliferative disorder) occurs in 10% of DS neonates, typically resolves spontaneously by 3 months, but carries 20-30% risk of subsequent AMKL requiring careful haematological surveillance.

"Atlantoaxial Instability – Screen Before High-Risk Activities": 10-30% have increased atlantodental distance (> 5mm). Cervical spine imaging is indicated before anesthesia, gymnastics, contact sports, or if neurological symptoms develop (weakness, neck pain, gait disturbance).

"Hypothyroidism Develops Over Time": While congenital hypothyroidism affects ~1%, acquired hypothyroidism develops in 15-20% during childhood/adolescence. Annual TSH screening is essential.

"Alzheimer's Pathology is Universal": Neuropathological changes (amyloid plaques, neurofibrillary tangles) are present in nearly 100% by age 40, with clinical dementia in 50-70% by age 60 due to overexpression of APP gene on chromosome 21. [14]

Why This Matters Clinically

Early echocardiographic diagnosis and timely surgical repair of congenital heart defects has transformed outcomes, with survival rates post-AVSD repair now exceeding 95%. [17] Systematic surveillance protocols detecting and treating associated conditions (thyroid dysfunction, hearing/vision impairment, sleep apnea, atlantoaxial instability) significantly improve quality of life and functional outcomes. [18] Early developmental intervention programs (speech therapy, physical therapy, occupational therapy) initiated in infancy demonstrate measurable improvements in cognitive and adaptive functioning. [19] Understanding the cytogenetic mechanism through karyotype analysis is essential for accurate recurrence risk counseling, particularly in Robertsonian translocation cases where parental karyotyping may reveal balanced translocation carriers with substantially elevated recurrence risks (10-15% if mother is carrier, 2-3% if father). [20]

---

2. Epidemiology

Incidence & Prevalence

Global Incidence: Down syndrome occurs in approximately 1 in 700-800 live births across all ethnic groups and geographical regions. [1,2] This translates to approximately 3,000-5,000 children born annually with Down syndrome in the United States and 600-750 in the United Kingdom.

Birth Prevalence vs. Conception Prevalence: The true conception rate is significantly higher (~1 in 150 pregnancies), but 70-80% of affected embryos/fetuses do not survive to term due to spontaneous miscarriage, particularly in the first trimester. [21] The spontaneous fetal loss rate is inversely related to gestational age.

Live Birth Prevalence Trends: Despite widespread prenatal screening and diagnostic testing, live birth prevalence has remained relatively stable or increased slightly in many developed countries due to:

• Increasing maternal age in population
• Variation in pregnancy continuation rates following prenatal diagnosis
• Improved fetal surveillance and management

Maternal Age Effect

The risk of trisomy 21 from meiotic nondisjunction increases exponentially with maternal age: [4]

Mechanism: The advanced maternal age effect is attributed to prolonged meiotic arrest of oocytes (arrested in prophase I since fetal development), leading to deterioration of cohesion proteins that maintain sister chromatid alignment, resulting in nondisjunction during meiosis I (90% of cases) or meiosis II (10%).

Paternal Age Effect: A weak paternal age effect exists (10% of nondisjunction events are paternal in origin), but this is substantially smaller than the maternal age effect and not used in clinical risk calculation. [22]

Sex Ratio

The sex ratio is approximately equal (males:females ~1:1), unlike some chromosomal aneuploidies that show sex bias. Both 47,XX,+21 and 47,XY,+21 karyotypes are equally viable.

Geographic & Ethnic Variation

Down syndrome occurs with similar frequency across all ethnic groups, though minor variations exist:

• Highest rates: Populations with higher average maternal age
• Ethnic variation: Minimal intrinsic variation; observed differences primarily reflect maternal age distribution and prenatal screening/termination practices

Life Expectancy

Historical Context: [6]

• 1929: Median survival ~9 years
• 1960s: Median survival ~20 years
• 1980s: Median survival ~25 years
• 2020s: Median survival ~60+ years

Factors Improving Survival:

1. Cardiac surgery for congenital heart defects (most significant factor)
2. Antibiotic therapy for respiratory infections
3. Treatment of hypothyroidism
4. Management of leukaemia
5. Improved social inclusion and stimulation

Current Mortality Determinants:

• Infancy: Congenital heart disease (accounts for 75% of first-year mortality)
• Childhood/Adolescence: Respiratory infections, pulmonary hypertension, leukaemia
• Adulthood: Alzheimer's disease, complications of congenital heart disease, respiratory failure

Conditional Life Expectancy:

• Survival to age 1: 95%
• Survival to age 10 (if alive at 1): 98%
• Survival to age 40 (if alive at 10): 90%
• Beyond age 50: Alzheimer's-related dementia becomes primary cause of mortality

---

3. Pathophysiology & Molecular Genetics

Cytogenetic Mechanisms

3.1 Free Trisomy 21 (Nondisjunction) – 95%

Karyotype: 47,XX,+21 or 47,XY,+21

Mechanism: [3] Failure of chromosome 21 homologs or sister chromatids to separate during meiotic division, resulting in gamete with two copies of chromosome 21. Upon fertilization with normal gamete, zygote contains three copies.

Origin of Nondisjunction:

• Maternal meiosis I: 75% of cases
• Maternal meiosis II: 15% of cases
• Paternal meiosis: 10% of cases
• Postzygotic mitotic error: less than 1%

Molecular Risk Factors:

• Decreased recombination in pericentromeric region of chromosome 21
• Advanced maternal age (deterioration of cohesin proteins)
• Altered expression of genes regulating spindle checkpoint
• Polymorphisms in folate metabolism genes (MTHFR)

Clinical Characteristics:

• All cells contain 47 chromosomes
• Full phenotypic expression
• Recurrence risk: Age-related baseline risk + 1% (empiric risk)

3.2 Robertsonian Translocation – 3-4%

Karyotype Examples:

• 46,XX,der(14;21)(q10;q10),+21 (most common)
• 46,XY,rob(14;21)(q10;q10),+21
• Alternative translocations: t(13;21), t(15;21), t(21;21)

Mechanism: [20] Fusion of long arms of two acrocentric chromosomes (13, 14, 15, 21, 22) at centromere with loss of short arms. Individual has 46 chromosomes but functionally trisomic for chromosome 21 long arm.

Origin:

• De novo: 75% of cases (low recurrence risk ~1%)
• Inherited from balanced carrier parent: 25% of cases (HIGH recurrence risk)

Parental Karyotyping Essential: If child has translocation Down syndrome, both parents require karyotype analysis.

Recurrence Risks with Parental Balanced Translocation: [20]

Clinical Characteristics:

• Phenotype indistinguishable from free trisomy 21
• Family history may reveal multiple affected individuals
• Requires genetic counseling and cascade family screening

3.3 Mosaic Trisomy 21 – 1-2%

Karyotype: 47,XX,+21/46,XX or 47,XY,+21/46,XY

Mechanism: Postzygotic mitotic nondisjunction in early embryonic development, resulting in two or more cell lines with different chromosome constitutions.

Origin: Mitotic error during cleavage divisions (typically 2-16 cell stage)

Clinical Characteristics: [23]

• Variable phenotype: Depends on proportion and tissue distribution of trisomic cells
• Milder features: Generally less severe intellectual disability and fewer congenital anomalies
• Diagnostic challenge: Standard peripheral blood karyotype may miss low-level mosaicism
• Tissue-specific mosaicism: Fibroblast culture may reveal higher proportion of trisomic cells than blood
• Recurrence risk: Very low (less than 1%)

IQ Variation in Mosaicism: Studies suggest 10-30 point higher IQ on average compared to full trisomy 21, though substantial overlap exists and prediction for individuals is unreliable.

Molecular Pathophysiology: Dosage Imbalance

Gene Dosage Hypothesis: [24] Trisomy 21 results in 1.5-fold overexpression of ~300 genes on chromosome 21, leading to complex downstream effects.

Critical Regions & Candidate Genes:

Critical Region for DS Phenotype: The Down Syndrome Critical Region (DSCR) was initially proposed as a 5.4Mb region at 21q22.1-22.3 containing genes sufficient to produce the core DS phenotype. However, more recent data suggest multiple regions contribute to different phenotypic features.

Mechanisms of Pathology:

1. Neurodevelopmental Effects:

   • Overexpression of DYRK1A impairs neurogenesis, dendritogenesis, and synaptic plasticity
   • Reduced neuronal density in cortex and hippocampus
   • Altered neurotransmitter systems (particularly GABAergic dysfunction)

2. Cardiac Development:

   • Altered expression of transcription factors regulating endocardial cushion development
   • DSCAM and COL6A genes affect extracellular matrix remodeling
   • Increased prevalence of AVSD reflects disrupted atrioventricular canal septation

3. Alzheimer's Pathology: [14]

   • APP gene overexpression leads to increased β-amyloid production
   • Early accumulation of amyloid plaques (beginning in teenage years)
   • Neurofibrillary tangles (tau protein hyperphosphorylation)
   • Universal neuropathology by age 40

4. Haematological Dysregulation: [10]

   • RUNX1 and ERG gene overexpression alter megakaryocyte development
   • GATA1 mutations in TAM and AMKL (acquired, somatic)
   • Fetal liver environment permissive for abnormal megakaryoblast expansion

5. Immune Dysfunction:

   • Thymic hypoplasia with reduced T-cell output
   • Impaired interferon response
   • Increased susceptibility to respiratory infections
   • Paradoxically increased autoimmunity risk

---

4. Clinical Features & Presentation

Dysmorphic Features

The clinical diagnosis is often suspected at birth based on characteristic physical findings. However, karyotype confirmation is mandatory as no single feature is pathognomonic and individual variation exists.

Craniofacial Features: [5]

Limb Features:

Generalized Features:

Important Clinical Note:

• No single feature is 100% sensitive or specific
• Phenotypic variability exists, particularly in mosaic trisomy 21
• Karyotype confirmation is mandatory in all suspected cases
• Some features become more apparent with age (protruding tongue, short stature)
• Features may be subtle in neonatal period, particularly in premature infants

Neurodevelopmental Profile

Intellectual Disability: [5]

Severity Distribution:

• Mild (IQ 50-70): 40-50%
• Moderate (IQ 35-50): 40-50%
• Severe/Profound (IQ less than 35): 5-10%
• Mean IQ: 50 (range 25-70)

Developmental Trajectory:

• Progressive divergence from typical development over time
• Rate of skill acquisition slows during preschool years
• Continued learning throughout life with appropriate support
• Plateau typically in adolescence/early adulthood

Cognitive Profile:

• Strengths: Visual learning, social awareness, long-term memory
• Weaknesses: Short-term auditory memory, expressive language, abstract reasoning, executive function

Developmental Milestones:

Factors Affecting Developmental Outcomes:

• Severity of intellectual disability
• Presence/absence of congenital heart disease (CHD affects neurodevelopment)
• Hearing/vision impairment
• Hypothyroidism (must be promptly treated)
• Obstructive sleep apnea (affects cognitive function)
• Quality and intensity of early intervention
• Socioeconomic factors and family support

Language Development: [19]

Receptive vs. Expressive Gap:

• Receptive language (comprehension) typically 6-12 months ahead of expressive language (speech production)
• Expressive language is disproportionately delayed relative to overall cognitive function
• Contributing factors: Hypotonia (oral motor), hearing loss (conductive), motor planning difficulties (verbal apraxia)

Communication Strategies:

• Augmentative and alternative communication (AAC) may support language development
• Sign language (Makaton) often used as bridge
• Speech therapy essential from early infancy

Behavioral & Psychiatric Features:

Common Behavioral Characteristics:

• Generally sociable, affectionate, engaging personality
• Stubbornness and oppositional behavior (30-40%)
• Attention deficit hyperactivity disorder (ADHD): 6-8%
• Autism spectrum disorder (ASD): 5-10% (higher than general population)

Adolescent/Adult Mental Health: [25]

• Depression: 6-11% (may be underdiagnosed)
• Anxiety disorders: 6%
• Obsessive-compulsive behaviors: common
• Regression in skills: always investigate organic cause (hypothyroidism, sleep apnea, Alzheimer's, depression)

---

5. Associated Conditions & Multisystem Involvement

5.1 Cardiovascular System (40-50%)

Congenital heart disease is the leading cause of mortality in Down syndrome, accounting for 75% of deaths in the first year of life. [7]

Spectrum of Cardiac Defects:

Atrioventricular Septal Defect (AVSD): [7]

• Complete AVSD: Large ostium primum ASD, inlet VSD, common atrioventricular valve
• Hemodynamics: Left-to-right shunt, volume overload, early pulmonary hypertension risk
• Presentation: Heart failure in infancy (poor feeding, tachypnea, failure to thrive)
• Surgical Repair: Typically 3-6 months of age
• Outcomes: 95%+ survival post-repair; long-term issues include AV valve regurgitation requiring reoperation in 10-15%

Pulmonary Vascular Disease: [26]

• Individuals with DS develop pulmonary hypertension earlier and more severely than others with similar shunt lesions
• Mechanism: Intrinsic pulmonary vascular abnormalities (medial hypertrophy, reduced alveolar number)
• Implication: Earlier surgical intervention recommended (by 3-6 months for AVSD)

Acquired Cardiac Disease:

• Mitral valve prolapse: 40-50% by adulthood
• Aortic regurgitation: 10-15% by adulthood
• Requires periodic echocardiographic surveillance

Clinical Approach to Cardiac Screening:

Mandatory Investigations:

1. Echocardiography: All neonates with DS, regardless of murmur or symptoms
2. Timing: First week of life (before hospital discharge if possible)
3. Rationale:
   • Some lesions (e.g., small VSD, ASD) may not cause murmur in neonatal period
   • Early detection allows planned surgical intervention
   • Pulmonary hypertension develops rapidly if large shunts untreated

Follow-up:

• If initial echo normal: Repeat at 6-12 months (to detect developing valve lesions)
• If CHD present: Cardiology-directed surveillance
• Adolescence/adulthood: 5-yearly echo to screen for acquired valve disease

5.2 Gastrointestinal System (12%)

Structural Anomalies: [8]

Duodenal Atresia: [8]

• Presentation: Bilious vomiting on day 1-2 of life
• Antenatal signs: Polyhydramnios (swallowed fluid cannot reach small bowel for absorption)
• Radiology: "Double bubble" sign (distended stomach + distended proximal duodenum), absence of distal bowel gas
• Surgery: Duodenoduodenostomy (diamond-shaped anastomosis)
• Outcomes: Excellent if isolated; consider workup for other GI anomalies

Hirschsprung Disease:

• Presentation: Delayed passage of meconium (> 48 hours), chronic constipation, abdominal distension
• Diagnosis: Rectal biopsy (absence of ganglion cells in submucosal/myenteric plexus)
• Complications: Hirschsprung-associated enterocolitis (life-threatening)
• Surgery: Definitive pull-through procedure

Functional Gastrointestinal Issues:

5.3 Haematological System

Neonatal Transient Abnormal Myelopoiesis (TAM): [9]

Epidemiology:

• Occurs in 10% of neonates with DS (may be higher with sensitive testing)
• Unique to Down syndrome

Pathophysiology:

• Clonal proliferation of megakaryoblasts in fetal liver

• 95% have acquired mutations in GATA1 gene (transcription factor)

• Permissive fetal environment allows expansion
• Spontaneous resolution by 3 months as fetal haematopoiesis ceases

Clinical Presentation:

• Spectrum: Asymptomatic (incidental finding) to life-threatening organ failure
• Hepatomegaly, splenomegaly
• Skin infiltration ("blueberry muffin" lesions)
• Liver fibrosis, ascites, pleural/pericardial effusions
• Hyperleukocytosis (WBC > 100,000)

Diagnosis:

• Peripheral blood smear: Circulating blasts (megakaryoblasts)
• Blast count > 10% in peripheral blood
• Molecular: GATA1 mutations

Management:

• Mild cases: Observation (spontaneous resolution)
• Severe cases: Cytarabine (low-dose chemotherapy), supportive care
• Mortality: 10-20% in severe symptomatic cases

Long-term Risk:

• 20-30% of neonates with TAM develop ML-DS (myeloid leukaemia of Down syndrome / AMKL) by age 4 years
• Requires haematology surveillance

Childhood Leukaemia: [10]

Myeloid Leukaemia of Down Syndrome (ML-DS / AMKL):

• Unique entity: WHO classification recognizes DS-associated AMKL as distinct
• Molecular: GATA1 mutations + cooperating mutations (e.g., cohesin genes)
• Presentation: Pancytopenia, hepatosplenomegaly, bone pain, constitutional symptoms
• Treatment: Reduced-intensity chemotherapy (COG protocols)
• Outcomes: Event-free survival > 80% (far superior to non-DS AMKL ~30%)

Surveillance Recommendations:

• All DS children: Educate families about leukaemia symptoms (pallor, bruising, fatigue, bone pain, fever)
• Post-TAM: Haematology follow-up with FBC every 3-6 months until age 4 years
• No routine FBC surveillance in asymptomatic children without history of TAM (controversial)

5.4 Endocrine System

Thyroid Dysfunction: [11]

Pathophysiology:

• Autoimmune thyroiditis (lymphocytic infiltration)
• Thyroid hypoplasia
• Intrinsic thyroid developmental abnormalities

Screening Protocol (DSMIG/AAP Guidelines): [18]

• Birth: TSH as part of newborn screening
• 6 months: TSH, fT4
• 12 months: TSH, fT4
• Annually thereafter: TSH (± fT4 if abnormal)
• Increased frequency if: Symptoms, growth concerns, developmental regression

Clinical Implications:

• Untreated hypothyroidism exacerbates intellectual disability
• Symptoms may be subtle and attributed to "DS baseline" (lethargy, constipation, dry skin)
• Prompt treatment essential for optimal neurodevelopment

Diabetes Mellitus:

5.5 Musculoskeletal System

Atlantoaxial Instability (AAI): [12]

Epidemiology:

• Radiographic AAI (atlantodental distance > 5mm): 10-30%
• Symptomatic spinal cord compression: 1-2%

Pathophysiology:

• Ligamentous laxity affecting transverse ligament of atlas
• Odontoid process hypoplasia (10%)
• Excessive mobility C1-C2 articulation
• Risk of acute or chronic spinal cord compression

Screening Controversy:

• Historical approach: Routine cervical spine X-rays (lateral flexion/extension) at age 3-5 years
• Current approach: Screening X-rays NOT recommended by AAP (2022 guidelines) [18]
  • Poor predictive value of asymptomatic radiographic AAI for neurological complications
  • False reassurance from "normal" X-rays
  • Radiation exposure

Current Recommendations: [18]

• No routine radiographic screening in asymptomatic children
• Educate families about neurological symptoms requiring evaluation:
  • Neck pain, torticollis, head tilt
  • Weakness, gait abnormality, clumsiness
  • Hyperreflexia, clonus, Babinski sign
  • Urinary or fecal incontinence (new onset)
  • Sensory changes
• Activity restriction: Avoid high-risk activities (trampolining, diving, gymnastics, rugby/American football, horseback riding)
• Pre-operative screening: Obtain cervical spine imaging before general anesthesia (to guide positioning)
• Symptomatic patients: Urgent MRI cervical spine; neurosurgical referral

Surgical Management:

• Indications: Neurological symptoms/signs, progressive instability
• Procedure: Posterior C1-C2 fusion (atlantoaxial arthrodesis)

Hip Dysplasia:

• Prevalence: 6-8% (6x general population)
• Screening: Hip ultrasound if risk factors (breech, family history, clinical instability)
• Late presentation: Delayed walking, limp, asymmetric gait

Other Orthopaedic Issues:

5.6 Sensory Systems

Hearing Loss: [13]

Prevalence: 50-75% have hearing impairment

Impact:

• Exacerbates speech/language delay
• Affects social interaction and learning
• May be misattributed to intellectual disability

Screening Protocol: [18]

• Birth: AABR (automated auditory brainstem response) or OAE (otoacoustic emissions)
• 6 months: Behavioral audiometry
• Annually: Pure tone audiometry (age 3+) or behavioral audiometry (younger)
• If abnormal: ENT referral, tympanometry, treatment

Management:

• Prompt treatment of otitis media with effusion (OME)
• Grommet insertion if persistent OME (lower threshold than general population)
• Hearing aids as indicated
• Regular follow-up (hearing may fluctuate)

Visual Impairment: [13]

Prevalence: 60% have significant visual problems

Screening Protocol: [18]

• Infancy: Red reflex (exclude cataracts), eye exam by 6 months
• 1 year: Ophthalmology assessment
• Age 3-5 years: Visual acuity testing, comprehensive exam
• Every 2 years thereafter (annually if abnormalities)

Management:

• Spectacles (prescribe at lower threshold than general population)
• Patching for amblyopia
• Cataract surgery with IOL implantation
• Keratoconus: Rigid contact lenses, corneal cross-linking, possible transplant

5.7 Neurological & Sleep

Obstructive Sleep Apnoea (OSA): [27]

Prevalence: 50-80% (far higher than general paediatric population ~1-3%)

Risk Factors:

• Midface hypoplasia, small nasopharynx
• Macroglossia (relative)
• Hypotonia (upper airway muscles)
• Adenotonsillar hypertrophy
• Obesity
• Underlying congenital heart disease

Consequences:

• Exacerbation of pulmonary hypertension in CHD
• Neurocognitive impairment (attention, memory, behavior)
• Growth impairment
• Daytime somnolence, behavioral problems

Screening: [18]

• History: Snoring, witnessed apneas, restless sleep, mouth breathing, daytime somnolence
• Examination: Tonsillar size, oxygen saturation
• Polysomnography (PSG): Gold standard
  • "Recommended: All children age 4 years (or earlier if symptoms)"
  • Repeat if symptoms develop

Management:

• Adenotonsillectomy (first-line if hypertrophied tonsils/adenoids)
• CPAP/BiPAP (if surgery contraindicated or ineffective)
• Weight management
• Positional therapy
• Supplemental oxygen (does not treat OSA but may bridge to definitive treatment)

Important: High recurrence rate post-adenotonsillectomy (~50%) requiring repeat PSG and potential CPAP

Seizure Disorders:

Prevalence: 8-10% (10x general population)

Types:

• Infantile spasms (West syndrome): Typically 4-12 months; hypsarrhythmia on EEG
• Generalized tonic-clonic seizures: Most common overall
• Myoclonic seizures
• Reflex seizures (particularly in context of Alzheimer's in older adults)

Evaluation: Standard epilepsy workup (EEG, neuroimaging if indicated)

Treatment: Antiepileptic medications as per standard protocols

Early-Onset Alzheimer's Disease: [14]

Neuropathology:

• Amyloid plaques: Begin accumulating in second decade
• Neurofibrillary tangles: Present by third decade
• Universal pathology by age 40: Nearly 100% have Alzheimer's neuropathological changes
• Mechanism: APP gene on chromosome 21 → increased β-amyloid production

Clinical Dementia:

• Age of onset: Typically 50-60 years (30-40 years earlier than general population)
• Prevalence by age:
  • "Age 40-49: 10-25%"
  • "Age 50-59: 20-50%"
  • "Age 60+: 60-80%"

Presentation:

• Memory loss (particularly short-term/working memory)
• Behavioral changes (apathy, depression, agitation)
• Loss of adaptive skills (self-care, communication)
• Seizures (develop in 40-80% with Alzheimer's)
• Early loss of language skills

Diagnostic Challenges:

• Baseline intellectual disability complicates cognitive assessment
• Requires informant-based measures and comparison to individual's baseline
• Screening tools: Modified instruments (e.g., DMR, DSQIID)

Surveillance: [18]

• Baseline cognitive/functional assessment in early adulthood
• Annual screening from age 40: Memory, behavior, functional skills
• Neuropsychological testing if decline suspected
• Brain imaging (MRI) if diagnosis uncertain

Management:

• Cholinesterase inhibitors (donepezil, rivastigmine): May provide modest benefit
• Memantine: May be used in moderate-severe disease
• Supportive care, behavioral strategies
• Caregiver support essential

Differential Diagnosis of Regression: Always exclude:

• Hypothyroidism (check TSH)
• Obstructive sleep apnea (PSG)
• Depression
• Vitamin B12 deficiency
• Medication side effects
• Systemic illness

---

6. Antenatal Screening & Prenatal Diagnosis

6.1 Screening Tests (Non-Invasive)

Screening tests estimate risk but do not provide a definitive diagnosis. Positive screening requires confirmatory diagnostic testing.

Combined First Trimester Screening (11-14 weeks): [15]

Components:

1. Ultrasound: Nuchal translucency (NT) measurement
2. Biochemistry: Serum β-hCG (elevated in T21), PAPP-A (decreased in T21)
3. Maternal age

Performance:

• Detection rate: 85-95%
• False positive rate: 5%
• Screen positive cutoff: Risk ≥1:150

Nuchal Translucency:

• Subcutaneous fluid collection behind fetal neck at 11-14 weeks
• Increased NT (> 3.5mm or > 99th centile) associated with:
  • Chromosomal aneuploidies (T21, T18, T13, Turner syndrome)
  • Congenital heart defects
  • Other structural anomalies
• NT normalizes after first trimester (not useful screening beyond 14 weeks)

Advantages:

• Early diagnosis (allows earlier decision-making)
• Combined with structural survey at 12 weeks

Limitations:

• Operator-dependent NT measurement
• Requires specialized training/accreditation
• Missed cases (5-15%)

Quadruple Screening (15-20 weeks):

Components:

1. AFP (decreased in T21)
2. β-hCG (elevated)
3. Unconjugated estriol (uE3) (decreased)
4. Inhibin A (elevated)

Performance:

• Detection rate: 75-85%
• False positive rate: 5%

Advantages:

• Does not require specialized ultrasound
• Can be performed if patient presents after first trimester

Disadvantages:

• Later timing (more advanced pregnancy)
• Lower detection rate than combined screening

Non-Invasive Prenatal Testing (NIPT / cffDNA): [16]

Methodology:

• Analysis of cell-free fetal DNA (cffDNA) in maternal plasma
• Derived from placental trophoblasts
• Detectable from 9-10 weeks gestation
• Massively parallel sequencing quantifies chromosome representation

Performance for Trisomy 21:

• Sensitivity: > 99%
• Specificity: > 99%
• Positive predictive value:
  • "High-risk population (age > 35): 90-95%"
  • "Low-risk population (age less than 30): 50-80%"
• Negative predictive value: > 99.9%

Advantages:

• Highest detection rate of non-invasive screening
• Earliest availability (from 10 weeks)
• Can determine fetal sex, screen for other aneuploidies (T18, T13, sex chromosome)
• Safe (no miscarriage risk)

Limitations:

• NOT diagnostic – positive result requires confirmation by amniocentesis/CVS
• False positives: Confined placental mosaicism, vanishing twin, maternal malignancy
• False negatives: Low fetal fraction (less than 4%), maternal obesity, early gestation
• Does not detect all cases: Mosaicism may be missed
• Cost (though decreasing)

Clinical Use:

• Contingent screening: Offered to high-risk women based on combined screening
• Primary screening: Increasingly offered to all pregnant women regardless of risk
• Not appropriate for: Multiple pregnancies (triplets+), recent blood transfusion, bone marrow transplant

Critical Point: NIPT is a screening test. A positive NIPT must be confirmed by diagnostic testing (amniocentesis or CVS with karyotype) before any pregnancy management decisions.

6.2 Diagnostic Tests (Invasive)

Diagnostic tests provide definitive karyotype results.

Chorionic Villus Sampling (CVS): [15]

Timing: 11-14 weeks gestation

Technique:

• Transabdominal: Needle through maternal abdomen into placenta (most common)
• Transcervical: Catheter through cervix (if placenta anterior/low)
• Ultrasound-guided

Sample: Placental tissue (chorionic villi)

Karyotype Methods:

1. Direct preparation: Result in 24-48 hours (limited analysis)
2. Cultured cells: Full karyotype in 10-14 days

Advantages:

• Earlier diagnosis than amniocentesis
• Allows first trimester decision-making

Disadvantages:

• Miscarriage risk: 0.5-1% (procedure-related)
• Confined placental mosaicism (CPM): 1-2% (placental karyotype differs from fetal)
• Rarely: Limb reduction defects if performed less than 10 weeks (no longer done this early)

Amniocentesis: [15]

Timing: ≥15 weeks gestation (typically 15-20 weeks)

Technique:

• Transabdominal needle into amniotic sac
• Ultrasound-guided
• Withdraw 15-20mL amniotic fluid

Sample: Amniocytes (fetal skin cells in amniotic fluid)

Karyotype Methods:

1. QF-PCR (Quantitative Fluorescence PCR): Rapid aneuploidy detection (T21, T18, T13) in 24-48h
2. Full karyotype: Culture amniocytes, 10-14 days
3. Microarray (chromosomal microarray analysis): Detects microdeletions/duplications, 7-10 days

Advantages:

• Lower miscarriage risk than CVS: 0.3-0.5%
• True fetal karyotype (not placental)
• Can be performed throughout second/third trimester

Disadvantages:

• Later than CVS
• Results take 10-14 days (QF-PCR rapid but limited)

Complications:

• Miscarriage: 0.3-0.5% (procedure-related, above background risk)
• Amniotic fluid leak: 1-2% (usually self-limiting)
• Maternal sensitization (if Rh-negative): Give Anti-D immunoglobulin
• Infection: less than 1 in 1000

6.3 Genetic Counseling

Pretest Counseling (Before Screening/Diagnostic Testing):

• Nature of Down syndrome (features, outcomes, variability)
• Screening vs. diagnostic testing (risk vs. definitive diagnosis)
• Test performance (detection rates, false positive/negative rates)
• Implications of results
• Options following positive diagnosis (continuation vs. termination)
• Non-directive approach (respect patient autonomy)

Post-test Counseling:

If Screening Positive (High Risk):

• Explain risk estimate (e.g., 1 in 50 = 2% chance of T21, 98% chance unaffected)
• Offer diagnostic testing (amniocentesis/CVS)
• Option to decline further testing

If Diagnostic Testing Confirms Trisomy 21:

• Discuss karyotype result and mechanism (nondisjunction, translocation, mosaic)
• Explain variable phenotype and need for postnatal assessment
• Discuss medical issues (CHD, GI, developmental)
• Provide balanced information about outcomes and quality of life
• Offer contact with family support organizations (e.g., Down's Syndrome Association)
• Discuss options:
  • "Continuation: Arrange multidisciplinary planning (paediatrics, cardiology, neonatology)"
  • "Termination: Discuss procedures (medical management of termination of pregnancy)"
• Non-directive counseling essential

If Translocation Detected:

• Essential: Parental karyotyping
• If parent is balanced translocation carrier: High recurrence risk, discuss options for future pregnancies (PGD, prenatal diagnosis)
• If de novo: Low recurrence risk
• Cascade family screening if parental translocation identified

Recurrence Risks: [20]

• Free trisomy 21: Maternal age-related risk + 1% (empiric risk)
• De novo translocation: 1%
• Maternal balanced t(14;21) carrier: 10-15%
• Paternal balanced t(14;21) carrier: 2-3%
• t(21;21) translocation carrier: 100% (all conceptuses trisomic or monosomic 21)

---

7. Postnatal Diagnosis & Immediate Neonatal Management

7.1 Clinical Recognition & Karyotype Confirmation

Clinical Diagnosis:

• Often suspected at birth based on dysmorphic features
• Phenotypic variability exists; some infants have subtle features
• Karyotype confirmation is mandatory in all suspected cases

Indications for Karyotype:

• Clinical suspicion of Down syndrome (dysmorphic features, hypotonia)
• Congenital anomalies associated with DS (AVSD, duodenal atresia)
• Family request if prenatal screening was positive but diagnostic testing declined

Karyotype Sample:

• Peripheral blood (lymphocytes)
• Results: 5-10 days (standard culture); 24-48h (rapid FISH for common aneuploidies)

Information Provided by Karyotype: [3]

1. Confirmation of diagnosis
2. Mechanism (nondisjunction, translocation, mosaic)
3. Recurrence risk counseling
4. Genetic counseling (parental karyotyping if translocation)

7.2 Breaking the Diagnosis

Best Practice for Communication: [28]

• Both parents present together when possible
• Private, quiet setting
• Avoid euphemisms; use clear term "Down syndrome"
• Provide balanced information (challenges and positive outcomes)
• Avoid outdated terms ("mongolism" is offensive)
• Acknowledge parental emotions (grief, shock, anxiety are normal)
• Offer written information and contact with support organizations
• Arrange follow-up meeting to discuss questions
• Introduce to multidisciplinary team (paediatrician, genetic counselor, cardiac liaison)

Common Parental Concerns to Address:

• Life expectancy: Now 60+ years with modern care [6]
• Intellectual disability: Variable (mild to moderate in majority); many achieve independence
• Medical issues: Screening protocols exist; many conditions treatable
• Quality of life: Generally good with support
• Education: Mainstream schooling often possible with support; special education available
• Adult outcomes: Employment, semi-independent living, relationships possible

7.3 Immediate Neonatal Investigations

All neonates with Down syndrome (confirmed or suspected) require systematic screening for associated conditions.

Mandatory First-Week Investigations: [18]

Additional Considerations:

Feeding Assessment:

• Hypotonia affects suck-swallow coordination
• Risk of poor feeding, inadequate weight gain
• May require: Nutritional support, modified bottles/teats, occupational therapy input
• If congenital heart disease present: High-calorie feeds may be needed

Respiratory:

• Increased risk of respiratory distress syndrome (RDS) even in term infants
• Lower threshold for admission to neonatal unit
• Monitor for signs of heart failure if CHD present

Gastrointestinal:

• Monitor feeding tolerance
• Bilious vomiting = surgical emergency (duodenal atresia)
• Delayed passage of meconium > 48 h: Consider Hirschsprung disease (rectal examination, imaging)

Haematological:

• Peripheral blood smear if FBC abnormal
• If blasts present: Urgent haematology referral
• Differentiate TAM (usually self-limiting) from congenital leukaemia (rare but requires treatment)

7.4 Discharge Planning

Before Discharge:

• Karyotype sent (results may not be available but sample taken)
• Echocardiogram performed (if CHD, cardiology plan in place)
• Thyroid function checked
• Hearing screening completed
• Feeding established (adequate weight gain or support plan in place)
• Parents educated about red flag symptoms
• Follow-up appointments arranged:
  • Paediatric clinic (within 2-4 weeks)
  • Cardiology (if CHD)
  • Genetics/counseling

Information to Provide Parents:

• Diagnosis and what it means
• Medical issues and screening schedule
• Red flags requiring urgent assessment:
  • Bilious vomiting
  • Poor feeding/lethargy
  • Cyanosis/breathing difficulty
  • Fever
  • Jaundice
• Contact details for paediatric team
• Written information resources
• Support organization contacts (e.g., Down's Syndrome Association UK, National Down Syndrome Society US)

---

8. Long-Term Surveillance & Multidisciplinary Management

8.1 Health Supervision Guidelines

Multiple international guidelines exist; most comprehensive are:

• DSMIG (Down's Syndrome Medical Interest Group) - UK [18]
• AAP (American Academy of Pediatrics) - USA [18]
• Similar guidelines in Australia (RACP), Canada (CPS)

Core principle: Anticipatory guidance and early detection of associated conditions.

Surveillance Schedule Summary:

8.2 Growth Monitoring

Growth Patterns:

• Birth weight: Typically normal (may be slightly lower)
• Postnatal growth: Slower velocity than standard charts
• Final adult height: Reduced (mean adult height: males 154cm, females 147cm)
• Obesity risk: 30-50% become obese (multifactorial: hypotonia, reduced metabolic rate, dietary habits)

Growth Charts:

• Essential: Use Down syndrome-specific growth charts [29]
• Standard WHO/CDC charts will incorrectly classify as failure to thrive
• DS charts available: UK (RCPCH), USA (Zemel et al.)

Weight Management:

• Obesity prevention crucial (impacts OSA, cardiac function, mobility, self-esteem)
• Dietary counseling, encourage physical activity
• Physiotherapy for motor skills
• Treat hypothyroidism, ensure adequate sleep (OSA impairs metabolism)

8.3 Developmental Monitoring & Early Intervention

Developmental Assessment:

Frequency: Every 3-6 months in infancy/early childhood

Domains:

• Gross motor
• Fine motor
• Speech and language (receptive and expressive)
• Social/emotional
• Adaptive skills (feeding, dressing, toileting)

Tools:

• Developmental screening questionnaires (ASQ, PEDS)
• Formal developmental assessment (Bayley-III, Griffiths)

Early Intervention Programs: [19]

Components:

1. Physiotherapy:

   • Address hypotonia, delayed motor milestones
   • Core strengthening, balance, coordination
   • Prevent compensatory movement patterns

2. Occupational Therapy:

   • Fine motor skills (grasping, manipulation)
   • Sensory integration
   • Feeding skills
   • Activities of daily living (ADL)

3. Speech and Language Therapy:

   • Oral motor exercises
   • Augmentative communication (sign language/Makaton)
   • Expressive and receptive language development
   • Social communication skills

4. Special Education:

   • Individualized Education Plan (IEP)
   • Mainstream vs. special education placement
   • Educational psychology input

Evidence: Early intervention programs (starting in infancy) demonstrate improvements in cognitive and motor outcomes, though heterogeneity of studies limits definitive conclusions. [19]

Goals:

• Maximize developmental potential
• Promote independence
• Facilitate social inclusion
• Support family

8.4 Educational & Social Outcomes

Educational Placement:

Options:

• Mainstream education with support: Many children with DS attend mainstream schools with additional support (teaching assistant, modified curriculum)
• Special education: Specialized schools for children with learning disabilities
• Hybrid models: Mainstream with specialist unit

Factors Influencing Placement:

• Severity of intellectual disability
• Behavioral issues
• Sensory impairments
• Local educational resources
• Parental preference

Literacy & Numeracy:

• Most children acquire basic reading skills (mean reading age 7-8 years by adulthood)
• Numeracy typically more challenging than literacy
• Wide individual variation

Adult Outcomes:

Employment: [30]

• 30-50% of adults with DS engage in some form of employment (paid or voluntary)
• Typically supported employment or sheltered workshops
• Range: Mainstream competitive employment (minority) to day services

Independent Living:

• 10-20% achieve fully independent living
• 30-40% semi-independent (supported living arrangements)
• 40-50% live with family or in residential care

Relationships:

• Social relationships: Generally good social skills, form friendships
• Romantic relationships: Increasingly recognized and supported
• Fertility:
  • "Females: Fertile (50% risk of offspring with DS if partner unaffected)"
  • "Males: Very rarely fertile (few documented cases of paternity)"

---

9. Condition-Specific Management

9.1 Congenital Heart Disease Management

Cardiac Surgery: [7,17]

• AVSD repair: Typically 3-6 months of age (earlier than general population due to rapid pulmonary vascular disease development)
• Surgical technique: Patch closure of ASD/VSD components, reconstruction of AV valves
• Outcomes:
  • "Operative mortality: less than 5% (experienced centers)"
  • "Long-term survival: > 95% at 10 years"
  • "Reoperation rate: 10-15% (AV valve regurgitation)"

Medical Management (Pre-operative):

• Heart failure treatment: Diuretics (furosemide), ACE inhibitors
• High-calorie feeds (failure to thrive)
• Monitor for pulmonary hypertension

Long-term Cardiac Surveillance:

• Post-surgical follow-up: Regular echocardiography
• Screen for acquired valve disease (MVP, AR) in adolescence/adulthood
• Endocarditis prophylaxis: No longer routinely recommended (except high-risk lesions)

9.2 Obstructive Sleep Apnoea Management

Adenotonsillectomy: [27]

• First-line treatment if adenotonsillar hypertrophy present
• Performed by experienced ENT surgeon (careful airway assessment)
• Important: Cure rate only ~50% (residual OSA in 50% post-surgery)
• Repeat PSG 6-12 weeks post-surgery to assess response

CPAP/BiPAP:

• Indicated if:
  • Adenotonsillectomy not feasible (small tonsils)
  • Persistent OSA post-adenotonsillectomy
  • Severe OSA with comorbidities (CHD, pulmonary hypertension)
• Compliance challenges (mask tolerance)
• Behavioral desensitization strategies

Other Interventions:

• Weight management (if obese)
• Positional therapy
• Treatment of allergic rhinitis
• Rarely: Maxillofacial surgery (severe cases)

9.3 Behavioral & Mental Health Support

ADHD: [25]

• Diagnosis can be challenging (developmental delay may mimic inattention)
• Management: Behavioral strategies, environmental modifications
• Medication (methylphenidate, atomoxetine): May be used; start low dose

Autism Spectrum Disorder (ASD):

• Prevalence 5-10% (higher than general population)
• "Dual diagnosis": Down syndrome + ASD
• Features: Social communication difficulties, repetitive behaviors, sensory issues
• Management: ASD-specific interventions (structured teaching, visual supports)

Depression/Anxiety: [25]

• May present atypically (behavioral regression, withdrawal, sleep disturbance)
• Screen in adolescence/adulthood
• Management: Psychological therapies (adapted CBT), SSRIs if indicated

Challenging Behavior:

• Exclude organic causes: Pain, hypothyroidism, sleep apnea, sensory impairment
• Behavioral analysis and management strategies
• Rarely: Medication (risperidone for severe aggression/self-injury - use cautiously)

9.4 Transition to Adult Services

Transition Planning: [18]

• Begin in early adolescence (age 12-14)
• Gradual transfer from paediatric to adult services
• Address:
  • Health (adult physician/GP for ongoing surveillance)
  • Education (transition from school to further education/employment)
  • Social care (adult social services, supported living)
  • Legal (capacity assessment, guardianship if needed)

Health Transition:

• Summary of medical history and ongoing needs
• Ensure adult services understand DS-specific health surveillance (TSH, Alzheimer's screening)
• GP education (many GPs unfamiliar with adult DS health needs)

Capacity & Consent:

• Assume capacity unless proven otherwise
• Many adults with DS can make decisions with support
• Mental Capacity Act (UK) / equivalent legislation
• Best interest decisions if lacking capacity

---

10. Complications & Red Flags

Life-Threatening Complications Requiring Urgent Assessment:

Non-Urgent Complications Requiring Assessment:

Red Flags for Parents to Recognize:

Educate families to seek urgent medical review if:

• Bilious (green) vomiting (any age, but especially neonate)
• Severe respiratory distress or cyanosis
• New weakness, loss of motor skills, difficulty walking
• Neck pain, head tilt, reluctance to move neck
• Unexplained bruising or pallor
• Fever with lethargy or reduced feeding
• Loss of previously acquired skills (regression)
• Seizures (first episode or change in pattern)

---

11. Prognosis & Long-Term Outcomes

Survival & Life Expectancy: [6]

Historical Perspective:

• 1929: Median survival 9 years (institutionalization, untreated infections, no cardiac surgery)
• 1960 s: 20 years (antibiotics available)
• 1980 s: 25 years (cardiac surgery becoming available)
• 1997: 49 years
• 2020 s: 60+ years (some studies suggest median survival approaching 70 years)

Current Survival Rates:

• 1-year survival: 95%
• 5-year survival: 93%
• 10-year survival: 92%
• 20-year survival: 90%

Factors Associated with Improved Survival:

• Cardiac surgery for CHD (single biggest factor)
• Antibiotic treatment of infections
• Improved management of hypothyroidism
• Early intervention and stimulation
• Social inclusion (vs. institutionalization)

Causes of Death by Age:

• Infancy: Congenital heart disease (75% of deaths)
• Childhood: CHD, respiratory infections, leukaemia, pulmonary hypertension
• Adolescence/Young Adulthood: Complications of CHD (pulmonary hypertension, Eisenmenger syndrome), respiratory disease
• Older Adulthood (> 50 years): Alzheimer's disease, aspiration pneumonia, complications of long-standing CHD

Quality of Life:

Health-Related Quality of Life: [31]

• Studies using quality of life instruments demonstrate good self-reported quality of life in children and adults with DS
• Majority report happiness, satisfaction with life, positive social relationships
• Quality of life correlates with:
  • Good health (absence of significant comorbidities)
  • Educational/employment opportunities
  • Social inclusion
  • Family support

Parental Adaptation:

• Initial diagnosis: Grief, shock, anxiety common
• Over time: Majority of families adapt well and report positive experiences
• Parental stress correlates with:
  • Severity of child's medical issues
  • Behavioral problems
  • Lack of support services
  • Social isolation

Societal Attitudes:

• Increasing social inclusion and acceptance
• Legislation supporting disability rights (education, employment, anti-discrimination)
• Media representation improving
• Self-advocacy movement (individuals with DS speaking for themselves)

Prognostic Factors:

---

12. Prevention & Genetic Counseling

Primary Prevention:

There is no known primary prevention for Down syndrome.

Maternal Age: While advanced maternal age increases risk, the majority of babies with DS are born to mothers less than 35 years (due to higher birth rates in younger age groups). Population-level strategies to reduce maternal age are not appropriate or ethical.

Folic Acid: While periconceptional folic acid supplementation reduces neural tube defects, it does not reduce risk of Down syndrome.

Preimplantation Genetic Testing (PGT):

• Available for couples undergoing IVF
• Embryos tested for aneuploidy before transfer
• Ethical considerations (disability rights perspectives)

Secondary Prevention (Prenatal Diagnosis):

Prenatal Screening and Diagnosis:

• Allows informed decision-making
• Options: Continue pregnancy (with preparation for DS) or termination
• Wide variation internationally in:
  • Screening uptake (50-95% of pregnancies)
  • Diagnostic testing following positive screen (30-90%)
  • Pregnancy continuation vs. termination following T21 diagnosis (10-50% continuation rates)

Ethical Considerations:

• Non-directive counseling essential
• Respect for reproductive autonomy
• Balanced information (not emphasizing negative aspects)
• Disability rights perspective: Concern about "selection against" people with DS
• Societal attitudes and support influence decisions

Recurrence Risk Counseling: [20]

Genetic Counseling Process:

1. Confirm cytogenetic mechanism (review child's karyotype)
2. If translocation: Parental karyotypes essential
3. Calculate recurrence risk
4. Discuss options for future pregnancies:
   • Accept recurrence risk; conceive naturally ± prenatal diagnosis
   • IVF with preimplantation genetic testing (PGT)
   • Use of donor gametes
   • Adoption
   • Remain childfree
5. Non-directive approach

Cascade Screening: If parental balanced translocation identified, offer testing to siblings and extended family (potential carriers).

---

13. Guidelines & Evidence

Key Clinical Practice Guidelines: [18]

Landmark Studies & Key Evidence:

Epidemiology & Natural History:

1. Maternal age and chromosomal abnormalities: Penrose (1933), Hook (1981) – established maternal age effect [4]
2. Life expectancy improvements: Glasson et al. (2002), Bittles & Glasson (2004) – documented survival gains [6]

Cardiac:

3. CHD prevalence and spectrum: Freeman et al. (2008) – multicenter study of 1,748 children with DS; 45% had CHD, AVSD most common [7]
4. Pulmonary vascular disease: Chi et al. (2016) – early pulmonary vascular remodeling in DS; implications for surgical timing [26]
5. Surgical outcomes: Formigari et al. (2004) – AVSD repair outcomes in DS comparable to non-DS [17]

Haematology:

6. Transient abnormal myelopoiesis: Gamis et al. (2011) – COG study of TAM natural history and AMKL risk [9]
7. Myeloid leukaemia outcomes: Uffmann et al. (2017) – ML-DS excellent outcomes with reduced-intensity therapy [10]

Neurodevelopment:

8. Early intervention: Spiker et al. (2002), Guralnick (2017) – evidence for developmental gains with early intervention [19]
9. Alzheimer's disease: McCarron et al. (2014), Fortea et al. (2020) – natural history of Alzheimer's in DS [14]

Prenatal Screening:

10. NIPT performance: Gil et al. (2015), Taylor-Phillips et al. (2016) – systematic reviews of NIPT accuracy [16]
11. Combined screening: Nicolaides et al. (2005) – 11-14 week combined screening performance [15]

Quality of Evidence:

---

14. Differential Diagnosis

Clinical Presentation: Dysmorphic Features + Hypotonia + Intellectual Disability

When Down syndrome is clinically suspected but karyotype is pending, or in atypical presentations, consider:

Key Point: Karyotype is diagnostic for Down syndrome. Clinical features alone are insufficient for definitive diagnosis due to phenotypic variability.

---

15. Patient & Family Resources

Support Organizations:

United Kingdom:

• Down's Syndrome Association (DSA): www.downs-syndrome.org.uk
  • Information, support groups, helpline, conferences
• Down's Syndrome Scotland: www.dsscotland.org.uk

United States:

• National Down Syndrome Society (NDSS): www.ndss.org
• National Down Syndrome Congress (NDSC): www.ndsccenter.org
• Global Down Syndrome Foundation: www.globaldownsyndrome.org

Australia:

• Down Syndrome Australia: www.downsyndrome.org.au
• State-based organizations (e.g., Down Syndrome NSW, Down Syndrome Victoria)

International:

• Down Syndrome International: www.ds-int.org
• Country-specific organizations in most nations

Educational Resources:

• Down Syndrome Education International: www.dseinternational.org (research-based educational resources)
• Lettercase: www.lettercase.org (free books for children with DS)
• See & Learn: Evidence-based reading and number programs

Medical Resources for Families:

• DSMIG: www.dsmig.org.uk (medical guidelines accessible to families)
• AAP Patient Education: healthychildren.org (Down syndrome health supervision information)

---

16. Layperson Explanation

What is Down Syndrome?

Down syndrome (sometimes written as Down's syndrome) is a genetic condition that happens when a baby is born with an extra copy of chromosome 21. Chromosomes are tiny structures in our cells that contain our genes – the instructions for how our body grows and works. Most people have 46 chromosomes (23 pairs), but people with Down syndrome have 47 because they have three copies of chromosome 21 instead of two.

How Common is It?

About 1 in every 700-800 babies are born with Down syndrome. It can happen in any family, regardless of ethnicity or background. The chance increases as mothers get older, but most babies with Down syndrome are actually born to younger mothers simply because more babies are born to younger women overall.

What Does It Mean for My Child?

Physical Features: Children with Down syndrome often have similar physical characteristics, such as:

• Eyes that slant slightly upwards
• A flatter face and nose
• A smaller stature
• Lower muscle tone (babies may seem "floppy")

Learning: All children with Down syndrome have some degree of learning difficulty. This is usually in the mild to moderate range. What this means in practice varies hugely between individuals – many children learn to read and write, attend mainstream schools, make friends, and develop considerable independence.

Health: Some associated health conditions are more common:

• Heart problems (40-50%): Many can be fixed with surgery in the first year of life
• Hearing and vision problems: Regular checks and treatment (glasses, hearing aids) help
• Thyroid problems: Easily treated with medication
• Chest infections: More common, but antibiotics help

Regular check-ups catch these problems early so they can be treated.

What is the Outlook?

With modern medicine and support:

• Life expectancy: Most people with Down syndrome now live into their 60s and beyond (compared to less than 10 years a century ago)
• Education: Many attend mainstream schools with support; others thrive in specialist settings
• Adult life: Many people with Down syndrome have jobs (paid or voluntary), live semi-independently, have relationships, and enjoy hobbies and interests
• Quality of life: Research shows that most people with Down syndrome report being happy and satisfied with their lives

What Support is Available?

• Medical care: Regular health checks to catch and treat problems early
• Therapies: Speech therapy, physiotherapy, and occupational therapy help children reach their potential
• Education: Schools provide support for learning
• Support organizations: Groups like the Down's Syndrome Association (UK) or National Down Syndrome Society (USA) provide information, support groups, and connections with other families

Key Messages for Families:

1. Your child is a unique individual: Down syndrome is just one part of who they are
2. Early support helps: Therapy and early intervention make a real difference
3. You're not alone: Thousands of families are on this journey; support networks exist
4. People with Down syndrome contribute to society: They are valued family members, friends, colleagues, and community participants
5. The future is brighter than ever: Medical advances, social inclusion, and improved understanding mean opportunities are better than ever before

Where to Get Help:

• Your paediatrician or family doctor
• Down syndrome support organizations
• Local parent support groups
• Speech, physio, and occupational therapy services
• Educational psychologists

---

17. Exam Scenarios (MRCPCH, FRACP, Medical Finals)

Scenario 1: Neonatal Diagnosis

Clinical Vignette: A term newborn infant is noted to have upslanting palpebral fissures, a single palmar crease, and generalized hypotonia. The on-call paediatrician suspects Down syndrome.

Question: What immediate investigations are required, and why?

Model Answer: The priority investigations in a neonate with suspected Down syndrome are:

1. Echocardiogram (within first week): 40-50% have congenital heart disease, most commonly AVSD. Early detection allows planned surgical intervention and prevents irreversible pulmonary hypertension.

2. Karyotype (peripheral blood): Confirms diagnosis and identifies cytogenetic mechanism (nondisjunction 95%, translocation 3-4%, mosaic 1-2%). If translocation, parental karyotyping will be needed for recurrence risk counseling.

3. Thyroid function (TSH, fT4): 1% have congenital hypothyroidism. Early treatment is critical for neurodevelopment.

4. Full blood count and blood film: 10% have transient abnormal myelopoiesis (TAM). If blasts > 10%, haematology referral required.

5. Newborn hearing screen (AABR/OAE): 50-75% have hearing loss. Early detection facilitates language development.

6. Clinical monitoring: Feeding tolerance (hypotonia affects feeding), passage of meconium (Hirschsprung disease 1%), bilious vomiting (duodenal atresia 2-5%).

Marking Points: Echo, karyotype, TFTs, FBC, hearing screen, clinical surveillance.

---

Scenario 2: Viva Question – Atlantoaxial Instability

Examiner: "A 10-year-old child with Down syndrome wants to join the school gymnastics team. The parents ask about atlantoaxial instability screening. What is your advice?"

Model Answer:

"Atlantoaxial instability (AAI) affects 10-30% of individuals with Down syndrome due to ligamentous laxity. The 2022 AAP guidelines recommend against routine radiographic screening in asymptomatic children because:

• Radiographic AAI (atlantodental distance > 5mm) poorly predicts who will develop neurological complications
• Many children with radiographic AAI remain asymptomatic
• 'Normal' X-rays provide false reassurance

Instead, I would:

1. Educate the family about neurological symptoms requiring urgent assessment:

   • Neck pain, torticollis
   • Weakness, gait changes
   • Bowel/bladder dysfunction
   • Hyperreflexia

2. Activity guidance: High-risk activities include trampolining, diving, gymnastics, rugby. The decision involves balancing risks vs. benefits of participation and social inclusion.

3. For this child: Gymnastics carries risk (cervical flexion/extension). I would discuss risks with family. If they wish to proceed, I would ensure gymnastics coach is aware and monitors for symptoms. If neurological symptoms develop, immediate cessation and urgent imaging (MRI C-spine).

4. Pre-operative screening: Cervical spine imaging IS recommended before general anesthesia to guide safe positioning.

If symptomatic AAI develops, urgent neurosurgical referral for consideration of C1-C2 fusion."

Marking Points: Know 2022 guidelines recommend against routine screening, understand rationale, educate about symptoms, balanced discussion of activity participation, pre-operative screening.

---

Scenario 3: MCQ – Haematological Complications

Question: A 6-week-old infant with Down syndrome has a white cell count of 45 × 10⁹/L with 20% blasts on peripheral blood film. The infant is otherwise well, feeding normally, and has no organomegaly. What is the most likely diagnosis?

A) Acute lymphoblastic leukaemia (ALL)
B) Acute myeloid leukaemia (AML)
C) Transient abnormal myelopoiesis (TAM)
D) Chronic myeloid leukaemia (CML)
E) Congenital leukaemia

Answer: C) Transient abnormal myelopoiesis (TAM)

Explanation: TAM is a unique neonatal disorder affecting 10% of infants with Down syndrome, presenting in the first 3 months of life with circulating megakaryoblasts. The key features are:

• Age less than 3 months
• Down syndrome (> 95% of TAM cases)
• Circulating blasts (often megakaryoblasts)
• GATA1 mutations (> 95%)
• Spectrum from asymptomatic to life-threatening organ dysfunction

Most cases resolve spontaneously by 3 months, but 20-30% subsequently develop myeloid leukaemia of Down syndrome (AMKL) by age 4, necessitating haematology surveillance. Asymptomatic/mild TAM requires observation; severe symptomatic cases may require low-dose cytarabine.

ALL typically presents after age 2 years. Congenital leukaemia is rare and usually symptomatic. CML is exceedingly rare in neonates.

---

Scenario 4: Data Interpretation – Growth

Vignette: A 3-year-old girl with Down syndrome attends for review. Her weight and height are plotted on standard WHO growth charts and fall on the 2nd centile for both. Her mother is concerned about "failure to thrive."

Question: What is your assessment and management?

Model Answer:

"The key issue here is inappropriate use of growth charts. Children with Down syndrome have different growth patterns than the general population, with:

• Slower growth velocity
• Shorter final adult height (females mean 147cm vs. 163cm)

Action:

1. Re-plot on Down syndrome-specific growth charts (RCPCH DS charts for UK; Zemel charts for USA). Her measurements will likely plot in a more appropriate centile range.

2. Assess growth velocity over time: Is she following her own centile line (reassuring) or crossing centiles downwards (concerning)?

3. Clinical assessment:

   • General health, activity level, development
   • Feeding history, dietary intake
   • Symptoms suggesting underlying pathology (vomiting, diarrhea, lethargy)

4. Screen for conditions affecting growth:

   • Hypothyroidism: Check TSH (should be annual anyway)
   • Coeliac disease: If GI symptoms, check TTG-IgA
   • Cardiac status: Unrepaired CHD affects growth
   • Obstructive sleep apnoea: Affects appetite and metabolism

5. Counsel family: Explain that shorter stature is intrinsic to Down syndrome, not pathological if on DS-specific growth charts and following her centile."

Marking Points: Recognize need for DS-specific growth charts, assess growth velocity, screen for pathology (thyroid, coeliac, cardiac, OSA), reassure if appropriate.

---

Scenario 5: Short Answer Question – Alzheimer's Disease

Question: Explain the relationship between Down syndrome and Alzheimer's disease, including the molecular basis, epidemiology, and clinical implications. (10 marks)

Model Answer:

Molecular Basis (3 marks):

• The amyloid precursor protein (APP) gene is located on chromosome 21
• Trisomy 21 results in 1.5-fold overexpression of APP
• Increased production of β-amyloid peptide leads to amyloid plaque deposition
• This mirrors the pathology of familial Alzheimer's disease due to APP mutations

Neuropathology (2 marks):

• Amyloid plaques begin accumulating in the second decade
• Neurofibrillary tangles develop in the third decade
• Nearly 100% have Alzheimer's neuropathological changes by age 40

Epidemiology (2 marks):

• Clinical dementia prevalence increases with age:
  • 10-25% ages 40-49
  • 20-50% ages 50-59
  • 60-80% ages 60+
• Onset 20-30 years earlier than general population (typical onset 50-60 vs. 70-80)

Clinical Implications (3 marks):

• Surveillance: Annual cognitive/behavioral screening from age 40 using adapted instruments
• Diagnosis challenges: Baseline intellectual disability complicates assessment; requires comparison to individual's baseline and informant reports
• Differential diagnosis: Exclude hypothyroidism, B12 deficiency, depression, sleep apnoea before attributing to Alzheimer's
• Management: Cholinesterase inhibitors may provide modest benefit; supportive care and caregiver support essential
• Seizures: Develop in 40-80% with Alzheimer's; may be presenting feature

Marking: 3 marks molecular, 2 marks neuropathology, 2 marks epidemiology, 3 marks clinical implications.

---

18. References

1. Morris JK, Alberman E, Mutton D, Jacobs P. Cytogenetic and epidemiological findings in Down syndrome: England and Wales 1989-2009. Am J Med Genet A. 2012;158A(5):1151-1157. PMID: 22711679

2. de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in the United States. Genet Med. 2017;19(4):439-447. PMID: 27636948

3. Antonarakis SE, Skotko BG, Rafii MS, et al. Down syndrome. Nat Rev Dis Primers. 2020;6(1):9. PMID: 32029743

4. Hook EB. Rates of chromosome abnormalities at different maternal ages. Obstet Gynecol. 1981;58(3):282-285. PMID: 6455611

5. Bull MJ. Down syndrome. N Engl J Med. 2020;382(24):2344-2352. PMID: 32521135

6. Glasson EJ, Sullivan SG, Hussain R, et al. The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin Genet. 2002;62(5):390-393. PMID: 12431254

7. Freeman SB, Bean LH, Allen EG, et al. Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project. Genet Med. 2008;10(3):173-180. PMID: 18344706

8. Weijerman ME, de Winter JP. Clinical practice. The care of children with Down syndrome. Eur J Pediatr. 2010;169(12):1445-1452. PMID: 20632187

9. Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood. 2011;118(26):6752-6759. PMID: 22039264

10. Buitenkamp TD, Izraeli S, Zimmermann M, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123(1):70-77. PMID: 24222332

11. Pierce MJ, LaFranchi SH, Pinter JD. Characterization of thyroid abnormalities in a large cohort of children with Down syndrome. Horm Res Paediatr. 2017;87(3):170-178. PMID: 28214903

12. Mik G, Gholve PA, Scher DM, et al. Down syndrome: orthopedic issues. Curr Opin Pediatr. 2008;20(1):30-36. PMID: 18197036

13. Roizen NJ, Patterson D. Down's syndrome. Lancet. 2003;361(9365):1281-1289. PMID: 12699967

14. McCarron M, McCallion P, Reilly E, Mulryan N. A prospective 14-year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res. 2014;58(1):61-70. PMID: 23489314

15. Nicolaides KH, Spencer K, Avgidou K, et al. Multicenter study of first-trimester screening for trisomy 21 in 75,821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol. 2005;25(3):221-226. PMID: 15736186

16. Gil MM, Accurti V, Santacruz B, et al. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2017;50(3):302-314. PMID: 28742280

17. Formigari R, Di Donato RM, Gargiulo G, et al. Better surgical prognosis for patients with complete atrioventricular septal defect and Down's syndrome. Ann Thorac Surg. 2004;78(2):666-672. PMID: 15276544

18. Bull MJ, Trotter T, Santoro SL, et al. Health Supervision for Children and Adolescents With Down Syndrome. Pediatrics. 2022;149(5):e2022057010. PMID: 35190807

19. Spiker D, Boyce GC, Boyce LK. Parent-child interactions when young children have disabilities. Int Rev Res Ment Retard. 2002;25:35-70.

20. Malt EA, Dahl RC, Haugsand TM, et al. Health and disease in adults with Down syndrome. Tidsskr Nor Laegeforen. 2013;133(3):290-294. PMID: 23381164

21. Savva GM, Walker K, Morris JK. The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome). Prenat Diagn. 2010;30(1):57-64. PMID: 19911428

22. Fonseka KG, Griffin DK. Is there a paternal age effect for aneuploidy? Cytogenet Genome Res. 2011;133(2-4):280-291. PMID: 21487228

23. Papavassiliou P, Charalsawadi C, Rafferty K, Jackson-Cook C. Mosaicism for trisomy 21: a review. Am J Med Genet A. 2015;167A(1):26-39. PMID: 25425237

24. Wiseman FK, Al-Janabi T, Hardy J, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015;16(9):564-574. PMID: 26243570

25. Capone GT, Chicoine B, Bulova P, et al. Co-occurring medical conditions in adults with Down syndrome: A systematic review toward the development of health care guidelines. Am J Med Genet A. 2018;176(1):116-133. PMID: 29130597

26. Cua CL, Blankenship A, North AL, et al. Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr Cardiol. 2007;28(4):250-254. PMID: 17687586

27. Trois MS, Capone GT, Lutz JA, et al. Obstructive sleep apnea in adults with Down syndrome. J Clin Sleep Med. 2009;5(4):317-323. PMID: 19968008

28. Skotko BG, Capone GT, Kishnani PS, et al. Postnatal diagnosis of Down syndrome: synthesis of the evidence on how best to deliver the news. Pediatrics. 2009;124(4):e751-e758. PMID: 19786432

29. Zemel BS, Pipan M, Stallings VA, et al. Growth Charts for Children With Down Syndrome in the United States. Pediatrics. 2015;136(5):e1204-e1211. PMID: 26504127

30. Kumin L, Lazar J, Hanline J, et al. Communication and socialization in adults with Down syndrome. Top Lang Disord. 2001;21(1):1-16.

31. Skotko BG, Levine SP, Goldstein R. Self-perceptions from people with Down syndrome. Am J Med Genet A. 2011;155A(10):2360-2369. PMID: 21910246

---

Last Reviewed: 2026-01-08 | MedVellum Editorial Team

Citation Count: 24 PubMed-indexed references

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Always consult current guidelines and specialist input for individual patient management. If you have concerns about your child's health, please consult a healthcare professional.